Premium
P2–072: Performance of preliminary cut‐points for progression from mild cognitive impairment to dementia of the Alzheimer's disease type using fully automated chemiluminescent beta‐amyloid 42 and tau assays
Author(s) -
Simon Adam,
Salamone Salvatore,
Clarke William,
Green George,
Soares Holly,
Burns Leah,
Baburina Irina,
Kozo Daniel,
Courtney Jodi,
Contestable Paul,
Jackson Shari,
Ajongwen Patience
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.715
Subject(s) - dementia , medicine , receiver operating characteristic , likelihood ratios in diagnostic testing , cognitive impairment , disease
P2-072 PERFORMANCE OF PRELIMINARY CUT-POINTS FOR PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO DEMENTIA OF THE ALZHEIMER’S DISEASE TYPE USING FULLY AUTOMATED CHEMILUMINESCENT BETAAMYLOID 42 AND TAU ASSAYS Adam Simon, Salvatore Salamone, William Clarke, George Green, Holly Soares, Leah Burns, Irina Baburina, Daniel Kozo, Jodi Courtney, Paul Contestable, Shari Jackson, Patience Ajongwen, AJ Simon Enterprises LLC., Yardley, Pennsylvania, United States; Saladax Biomedical, Inc., Bethlehem, New Jersey, United States; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States; Bristol Myers Squibb, Princeton, New Jersey, United States; Bristol Myers Squibb, Wallingford, New Jersey, United States; Bristol-Myers Squibb, Wallingford, New Jersey, United States; Saladax Biomedical, Bethlehem, Pennsylvania, United States; Ortho Clinical Diagnostics, Rochester, New York, United States; Ortho Clinical Diagnostics, Rochester, New York, United States. Contact e-mail: ssalamone@saladax.com